Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Glenmark Pharmaceuticals Ltd gained for a third straight session today. The stock is quoting at Rs 2315, up 2.18% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.19% on the day, quoting at 22705.75. The Sensex is at 73291.61, down 0.42%. Glenmark Pharmaceuticals Ltd has slipped around 5.18% in last one month.
Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has slipped around 1.54% in last one month and is currently quoting at 26267.25, up 0.96% on the day. The volume in the stock stood at 2.34 lakh shares today, compared to the daily average of 6.53 lakh shares in last one month.
The benchmark November futures contract for the stock is quoting at Rs 2316.6, up 1.43% on the day. Glenmark Pharmaceuticals Ltd is up 25.59% in last one year as compared to a 12.85% slide in NIFTY and a 18.23% slide in the Nifty Pharma index.
The PE of the stock is 43.86 based on TTM earnings ending June 26.
Glenmark Therapeutics Inc., USA (Glenmark) announced the launch of Adapalene Gel USP, 0.1% (OTC) in new pump packs. Glenmark's Adapalene Gel USP, 0.1% can be compared to the active ingredient of Differin®2 Gel, 0.1%.
According to Nielsen® syndicated data for the latest 52-week period ending 05 September2026, the Differin® Gel, 0.1% (OTC) market achieved annual sales of approximately $45.8 million.
The inspection was conducted at the Company's manufacturing facility from 22 June 2026 to 30 June 2026.
The American drug regulatory has granted a voluntary action indicated (VAI) status to the said facility.
The inspection was conducted at the Company’s manufacturing facility from 22 June 2026 to 30 June 2026.
The announcement was made during market hours today.
Glenmark Pharmaceuticals manufactures pharmaceutical formulations and active pharmaceutical ingredients, which it markets in India and abroad. It also undertakes R&D on new chemical and biological entities. The company has 10 manufacturing facilities spread across India, USA and a few other countries.
The company's consolidated net profit surged 930.34% to Rs 482.92 crore in the quarter ended June 2026 as against Rs 46.87 crore during the previous quarter ended June 2025. Revenue rose by 28.52% to Rs 3,931.73 crore in Q1 FY27 over Q1 FY26.
The scrip rose 0.49% to currently trade at Rs 2475 on the BSE.
Glenmark Pharmaceuticals Ltd is up for a fifth straight session today. The stock is quoting at Rs 2462.3, up 0.5% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.29% on the day, quoting at 23345.95. The Sensex is at 74600.56, down 0.35%. Glenmark Pharmaceuticals Ltd has gained around 2.99% in last one month.
Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 2.24% in last one month and is currently quoting at 27021.15, down 0.34% on the day. The volume in the stock stood at 1.45 lakh shares today, compared to the daily average of 4.99 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 2452.8, up 0.09% on the day. Glenmark Pharmaceuticals Ltd is up 22.09% in last one year as compared to a 7.25% slide in NIFTY and a 20.76% slide in the Nifty Pharma index.
The PE of the stock is 47.36 based on TTM earnings ending June 26.
Glenmark Specialty S.A., a wholly owned subsidiary of Glenmark Pharmaceuticals (Glenmark), today announced the launch of RYALTRIS® Nasal Spray in Brazil for the treatment of moderate to severe symptoms associated with allergic rhinitis (AR) in adults and adolescents of 12 years of age and older.
The launch follows regulatory approval granted by the Brazilian Health Regulatory Agency, Agência Nacional de Vigilância Sanitária (ANVISA) earlier this year.
The launch reflects Glenmark's continued commitment to advancing its respiratory innovation journey and reinforces the Company's continued progress in expanding access to differentiated therapies across global markets.
Allergic rhinitis is a highly prevalent chronic condition in Brazil, affecting an estimated 20–30% of the population, equivalent to nearly 40–60 million people2,3. This significant disease burden highlights the need for effective, convenient, and differentiated treatment options for patients across the country.
The launch of RYALTRIS® introduces the first olopatadine-containing intranasal combination therapy in Brazil, combining an antihistamine (olopatadine hydrochloride) and a corticosteroid (mometasone furoate) in a single nasal spray. This offers a differentiated dual-action treatment option for symptoms associated with allergic rhinitis.
Glenmark Pharmaceuticals Ltd rose for a third straight session today. The stock is quoting at Rs 2443.1, up 1.8% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.23% on the day, quoting at 24277.5. The Sensex is at 77655.51, down 0%. Glenmark Pharmaceuticals Ltd has added around 11.25% in last one month.
Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has added around 2.83% in last one month and is currently quoting at 26564, up 0.43% on the day. The volume in the stock stood at 3.53 lakh shares today, compared to the daily average of 5.16 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 2459.5, up 2.19% on the day. Glenmark Pharmaceuticals Ltd is up 26.13% in last one year as compared to a 0.91% fall in NIFTY and a 22.33% fall in the Nifty Pharma index.
The PE of the stock is 46.3 based on TTM earnings ending June 26.
Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch of Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL) Single-Dose Vials, 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package. Glenmark's Calcium Gluconate Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Calcium Gluconate Injection, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) and 10,000 mg/100 mL (100 mg/mL), of Fresenius Kabi USA, LLC [NDA 208418].
According to IQVIA® sales data for the 12-month period ending June 2026, the Calcium Gluconate Injection, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) and 10,000 mg/100 mL (100 mg/mL) market2 achieved annual sales of approximately $69.9 million